These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8960716)

  • 21. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease.
    Maher-Edwards G; Zvartau-Hind M; Hunter AJ; Gold M; Hopton G; Jacobs G; Davy M; Williams P
    Curr Alzheimer Res; 2010 Aug; 7(5):374-85. PubMed ID: 20043816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Farlow MR; Cyrus PA
    Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenserine efficacy in Alzheimer's disease.
    Winblad B; Giacobini E; Frölich L; Friedhoff LT; Bruinsma G; Becker RE; Greig NH
    J Alzheimers Dis; 2010; 22(4):1201-8. PubMed ID: 20930279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
    Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
    Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
    Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
    Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
    Xiao S; Chan P; Wang T; Hong Z; Wang S; Kuang W; He J; Pan X; Zhou Y; Ji Y; Wang L; Cheng Y; Peng Y; Ye Q; Wang X; Wu Y; Qu Q; Chen S; Li S; Chen W; Xu J; Peng D; Zhao Z; Li Y; Zhang J; Du Y; Chen W; Fan D; Yan Y; Liu X; Zhang W; Luo B; Wu W; Shen L; Liu C; Mao P; Wang Q; Zhao Q; Guo Q; Zhou Y; Li Y; Jiang L; Ren W; Ouyang Y; Wang Y; Liu S; Jia J; Zhang N; Liu Z; He R; Feng T; Lu W; Tang H; Gao P; Zhang Y; Chen L; Wang L; Yin Y; Xu Q; Xiao J; Cong L; Cheng X; Zhang H; Gao D; Xia M; Lian T; Peng G; Zhang X; Jiao B; Hu H; Chen X; Guan Y; Cui R; Huang Q; Xin X; Chen H; Ding Y; Zhang J; Feng T; Cantillon M; Chen K; Cummings JL; Ding J; Geng M; Zhang Z
    Alzheimers Res Ther; 2021 Mar; 13(1):62. PubMed ID: 33731209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.